ERDOSTEINE – 150 mg Capsules / 300 mg Capsules / Oral Suspension

Active Ingredient: Erdosteine
Pharmaceutical Forms:
• Erdosteine 150 mg Capsules
• Erdosteine 300 mg Capsules
• Erdosteine Syrup / Oral Suspension
Pharmacological Class: Mucolytic / Expectorant agent
ATC Classification: R05CB15

Medical Description

Erdosteine is a mucolytic agent used for the management of acute and chronic respiratory disorders associated with excessive or thick mucus production. It works by reducing mucus viscosity and improving mucociliary clearance, helping patients clear airway secretions more effectively and facilitating expectoration. In addition to its mucolytic activity, erdosteine demonstrates antioxidant and anti-inflammatory properties that may contribute to improved respiratory function and symptom control in selected patients.

Mechanism of Action

Erdosteine is a prodrug that becomes pharmacologically active after hepatic metabolism. Active metabolites release sulfhydryl (thiol) groups that:

• Break disulfide bonds within mucus glycoproteins, reducing sputum viscosity and elasticity
• Improve mucociliary transport and facilitate mucus clearance
• Scavenge free radicals and reduce oxidative stress
• Reduce inflammatory activity associated with respiratory disorders
• Demonstrate anti-adhesion effects that may enhance antibiotic penetration and activity in respiratory secretions

Indications / Uses

Erdosteine may be used for the symptomatic management of respiratory disorders associated with excessive mucus production, including:

• Acute bronchitis
• Chronic bronchitis
• Acute exacerbations of chronic bronchitis
• Chronic obstructive pulmonary disease (COPD) with mucus hypersecretion
• Upper and lower respiratory tract conditions associated with difficult sputum expectoration
• Respiratory conditions requiring improvement of mucus clearance according to physician assessment

Dosage and Administration

Dosage should be individualized according to patient age, body weight, formulation, and physician recommendations.

Adults
• Erdosteine 300 mg capsules: commonly administered twice daily depending on indication and treatment duration
• Erdosteine 150 mg capsules: dosing may vary according to clinical needs and local prescribing information

Pediatric Patients
• Erdosteine syrup/oral suspension may be used according to age and body weight following healthcare professional instructions

Administration recommendations may differ according to regional product labeling and approved prescribing information.

Possible Side Effects

Reported adverse reactions may include:

• Nausea
• Vomiting
• Abdominal discomfort
• Diarrhea
• Dyspepsia
• Headache
• Dizziness
• Skin rash or hypersensitivity reactions

Most reported adverse events are mild and transient. Patients should seek medical advice if severe reactions occur.

Precautions

• Use with caution in patients with severe hepatic impairment
• Use with caution in patients with severe renal impairment
• Patients with a history of hypersensitivity to erdosteine or formulation ingredients should avoid use
• Pregnancy and breastfeeding use should be based on physician evaluation of benefit-risk profile

References:

1. PubMed – Erdosteine Review
2. PubMed – Pharmacology and Clinical Efficacy of Erdosteine
3. PubMed Central (PMC) – Mucoactive Agents and Erdosteine Mechanisms
4. PubChem – Erdosteine Drug Information

Patient Disclaimer

This information is intended for educational purposes only and does not replace consultation with a physician, pharmacist, or other qualified healthcare professional. Patients should use Erdosteine only according to medical advice and approved prescribing information. Do not self-diagnose or alter treatment without consulting a healthcare professional. Seek immediate medical attention if allergic reactions, breathing difficulty, or severe adverse effects occur.